Three Arch Partners

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients suffering from acute and chronic liver diseases. The company's primary focus is on its lead product, OCR-002, an ammonia scavenger designed to address hyperammonemia through both intravenous and oral formulations. Recently, Ocera completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and potential future development pathways for its therapeutics.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

MEI Pharma, Inc. is a late-stage pharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for cancer treatment. The company's clinical pipeline includes several key drug candidates such as Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor currently in Phase II trials for relapsed follicular lymphoma, and Voruciclib, an oral cyclin-dependent kinase inhibitor under investigation for acute myeloid leukemia and B-cell malignancies in Phase Ib trials. Additionally, MEI Pharma is developing ME-344, a mitochondrial inhibitor targeting HER2-negative breast cancer, and Pracinostat, an oral histone deacetylase inhibitor being tested for myelodysplastic syndrome. The company has established various collaborations and agreements with notable partners, including Kyowa Kirin Company and BeiGene, to support its clinical development efforts. Founded in 2000, MEI Pharma has evolved significantly since its inception and continues to focus on advancing its promising oncology therapies.

Access Closure, Inc. is a medical device company based in Mountain View, California, founded in 2002. The company specializes in developing access site management products focused on vascular closure during interventional and diagnostic procedures. Its primary offering is the Mynx delivery system, a vascular closure device designed to seal arteriotomies using a unique water-soluble and extravascular sealant. This sealant expands within the tissue tract by absorbing blood and subcutaneous fluids, effectively addressing the complexities associated with vascular closure. Access Closure aims to enhance patient outcomes and procedural efficiency in the field of vascular access.

iScience Interventional specializes in developing innovative medical technologies for ophthalmic interventions. They focus on creating advanced microcatheters and imaging systems, enabling eye specialists to precisely administer therapies to specific locations within the eye. Additionally, they offer medical devices for canaloplasty procedures.

Access Closure, Inc. is a medical device company based in Mountain View, California, founded in 2002. The company specializes in developing access site management products focused on vascular closure during interventional and diagnostic procedures. Its primary offering is the Mynx delivery system, a vascular closure device designed to seal arteriotomies using a unique water-soluble and extravascular sealant. This sealant expands within the tissue tract by absorbing blood and subcutaneous fluids, effectively addressing the complexities associated with vascular closure. Access Closure aims to enhance patient outcomes and procedural efficiency in the field of vascular access.

Inova Labs, Inc. is a medical device development and manufacturing company based in Austin, Texas. Established in 2002, it specializes in creating innovative products for direct patient care, particularly focusing on oxygen delivery solutions for individuals with respiratory conditions. The company’s flagship products include the LifeChoice stationary and portable oxygen concentrators, which utilize a pulse mode system to provide varying levels of supplemental oxygen. Inova Labs also offers a range of accessories, such as carrying cases, external batteries, and power adapters. These products are distributed through authorized providers, primarily via their online platforms, ensuring accessibility for patients in need of oxygen therapy.

Salveo Specialty Pharmacy is an independent specialty pharmacy focused on delivering a comprehensive range of medications and clinical services to patients with chronic conditions. The company emphasizes enhancing the wellness and health of its patients by facilitating effective communication among customers, referral sources, and insurance plans. Salveo combines expertise in specialty pharmacy, home infusion, and home healthcare, ensuring that patients receive the appropriate clinical care tailored to their specific needs. Through its dedication to patient support, Salveo aims to achieve a superior level of care for individuals managing chronic illnesses.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

Crux Biomedical, Inc. was founded in August 2004 by physicians Tom Fogarty and Frank Arko, who aimed to address the clinical limitations of existing vena cava filters. The company specializes in the development of the Crux VCF System, a preventive device designed to mitigate the risk of pulmonary embolisms. This innovative system effectively prevents blood clots from traveling to the lungs, making it particularly beneficial for patients who are at risk of pulmonary embolism but are unable to tolerate blood thinners. Through its focus on improving patient outcomes, Crux Biomedical addresses a critical need in the management of venous thromboembolism.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

Tibion Corporation is a medical device company based in Moffett Field, California, specializing in the design and development of bionic devices aimed at enhancing mobility for individuals with impairments. Founded in 2002, the company focuses on non-invasive technologies that provide actively-assisted mobility enhancement and rehabilitation for those recovering from surgeries, strokes, or experiencing age-related muscle loss. Its flagship product, the PowerKnee, is a wearable bionic device designed to support leg rehabilitation, improve muscle strength, and assist users in daily activities. By leveraging advancements in orthotics, biomechanics, and embedded control systems, Tibion's products aim to significantly improve the quality of life for individuals with lower extremity dysfunction.

VisionCare Ophthalmic Technologies, Inc., established in 1997 and headquartered in Saratoga, California, is a specialty medical device company dedicated to improving vision for individuals with untreatable retinal disorders. The company focuses on the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices. Its flagship product, the Implantable Miniature Telescope (IMT), is an FDA-approved device designed to enhance vision in patients with end-stage age-related macular degeneration (AMD). The IMT is integral to the CentraSight treatment program, which guides patients through diagnosis, surgical evaluation, and postoperative care. VisionCare's mission is to restore visual functionality and improve quality of life for individuals with untreatable retinal disorders, primarily focusing on End-Stage AMD, the leading cause of blindness in older Americans.

TriReme Medical, Inc. is a privately held medical device company located in Pleasanton, California, founded in 2005. The company specializes in the development, manufacturing, and distribution of advanced therapeutic technologies aimed at treating complex vascular diseases, particularly coronary artery disease (CAD) and peripheral vascular disease. TriReme Medical focuses on creating innovative stent and balloon therapies tailored for challenging anatomical scenarios, such as bifurcations, addressing significant clinical needs in these areas. By providing physicians with differentiated devices, the company aims to enhance patient outcomes in complex coronary and peripheral interventions.

Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.

Ingenuity Systems is a developer of a software platform designed to support life science researchers by facilitating access to critical information. The platform enables enterprise customers to provide their researchers with resources through internal portals, search engines, and various software and workflow sources. This functionality allows researchers to effectively search, explore, visualize, and analyze biological and chemical data pertaining to genes, proteins, and small molecules, thereby enhancing their research capabilities and productivity in the life sciences field.

Calistoga Pharmaceuticals, Inc. specializes in developing innovative oral medications that target specific isoforms of the PI3 kinase pathway, aiming to enhance the health outcomes of patients suffering from cancer and inflammatory diseases. This critical cellular pathway plays a significant role in cell survival and the activation of immune cells. The company's lead product, CAL-101, is an oral delta-isoform selective PI3K inhibitor that has shown promising clinical responses in patients with B-cell malignancies and is currently under evaluation in various clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals has a robust pipeline of proprietary compounds that selectively inhibit other isoforms of the PI3K pathway, which are in early preclinical development or poised for initial clinical trials targeting cancer and inflammatory conditions.

Baxano, Inc. is a medical device company specializing in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Founded in 2005 and based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in the foramen, lateral recess, and central canal, catering to patients with varying degrees of spinal stenosis. Baxano's product lineup includes the Neuro Check device, which enables surgeons to verify safe positioning against the bone while ensuring the nerve is adequately protected. Additionally, it features the MicroBlade Shaver, an instrument for removing impinging bone and ligament, along with essential accessories such as guidewires, probes, and distal handles.

Voyage Medical, Inc. is a company that specializes in the manufacturing of cardiac medical devices aimed at treating atrial fibrillation, a common heart rhythm disorder. Established in 2006, the company is located in Redwood City, California. Voyage Medical focuses on developing innovative solutions to improve patient outcomes in the field of cardiology.

Hemosphere developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction.

Access Closure, Inc. is a medical device company based in Mountain View, California, founded in 2002. The company specializes in developing access site management products focused on vascular closure during interventional and diagnostic procedures. Its primary offering is the Mynx delivery system, a vascular closure device designed to seal arteriotomies using a unique water-soluble and extravascular sealant. This sealant expands within the tissue tract by absorbing blood and subcutaneous fluids, effectively addressing the complexities associated with vascular closure. Access Closure aims to enhance patient outcomes and procedural efficiency in the field of vascular access.

Free & Clear, Inc. specializes in providing phone-based tobacco treatment services to employers, health plans, and government agencies. The company offers comprehensive tobacco cessation programs, including the Quit For Life Program, which is designed to help employees and members of private organizations quit smoking and using smokeless tobacco through clinically proven methods. In addition, Free & Clear addresses broader health risks associated with chronic diseases by offering the Mind & Body Program, a behavior change solution aimed at helping individuals achieve and maintain a healthy weight. Through these services, Free & Clear aims to promote healthier lifestyles and reduce the impact of tobacco use on public health.

Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

Visiogen, Inc. is an ophthalmic medical device company focused on creating innovative vision solutions for cataract patients, including those with presbyopia. The company's flagship product is the Synchrony dual optic accommodating intraocular lens (IOL), designed to deliver a seamless vision experience across near, intermediate, and distance ranges without the need for corrective eyewear. To enhance surgical efficiency, the Synchrony IOL is supplied in a pre-loaded injector, minimizing lens handling during procedures. This advanced technology has received CE Mark approval in Europe and is currently undergoing clinical trials in the United States, reflecting Visiogen's commitment to improving patient outcomes in cataract surgery.

iScience Interventional specializes in developing innovative medical technologies for ophthalmic interventions. They focus on creating advanced microcatheters and imaging systems, enabling eye specialists to precisely administer therapies to specific locations within the eye. Additionally, they offer medical devices for canaloplasty procedures.

Calistoga Pharmaceuticals, Inc. specializes in developing innovative oral medications that target specific isoforms of the PI3 kinase pathway, aiming to enhance the health outcomes of patients suffering from cancer and inflammatory diseases. This critical cellular pathway plays a significant role in cell survival and the activation of immune cells. The company's lead product, CAL-101, is an oral delta-isoform selective PI3K inhibitor that has shown promising clinical responses in patients with B-cell malignancies and is currently under evaluation in various clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals has a robust pipeline of proprietary compounds that selectively inhibit other isoforms of the PI3K pathway, which are in early preclinical development or poised for initial clinical trials targeting cancer and inflammatory conditions.

SpinalMotion is a private company focused on preserving spinal motion for patients suffering from degenerative disc disease. Founded in 2004, the company specializes in the development of innovative artificial disc implants that utilize proprietary Kineflex Technology, designed to maintain the natural movement of the spine while offering low wear and improved longevity. Since obtaining FDA approval in 2005 to conduct clinical trials for lumbar and cervical artificial discs in the United States, SpinalMotion has built on its international clinical experience to enhance patient outcomes. The company has attracted investment from notable partners, including Southern Medical, Three Arch Partners, Skyline Ventures, and MedVenture Associates, to further its mission of enabling patients to lead pain-free and healthy lives.

WaveRx, Inc. went out of business. WaveRx, Inc. operates as a medical device company that develops technologies and products for dermatological disorders of the nail and skin. WaveRx, Inc. was formerly known as ID Wave Systems and changed its name to WaveRx, Inc. in October 2005. The company was incorporated in 2004 and is based in Waltham, Massachusetts.

Arete Therapeutics is a pharmaceutical company that develops small molecule therapeutics for diabetes and cardiovascular disease.

Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Baxano, Inc. is a medical device company specializing in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Founded in 2005 and based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in the foramen, lateral recess, and central canal, catering to patients with varying degrees of spinal stenosis. Baxano's product lineup includes the Neuro Check device, which enables surgeons to verify safe positioning against the bone while ensuring the nerve is adequately protected. Additionally, it features the MicroBlade Shaver, an instrument for removing impinging bone and ligament, along with essential accessories such as guidewires, probes, and distal handles.

Voyage Medical, Inc. is a company that specializes in the manufacturing of cardiac medical devices aimed at treating atrial fibrillation, a common heart rhythm disorder. Established in 2006, the company is located in Redwood City, California. Voyage Medical focuses on developing innovative solutions to improve patient outcomes in the field of cardiology.

Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

Eleme Medical, Inc. is a venture-backed aesthetics company specializing in advanced technologies for body shaping. The company has developed the SmoothShapes® product line, including the recently launched SmoothShapes® XV, which aims to transform cellulite treatment and enhance pre- and post-liposuction care. This innovative device features 50% more laser power and incorporates audible and visual treatment guidance, all within a portable design, making it suitable for various medical practices. Both SmoothShapes systems leverage the proprietary Photomology® platform, which combines dynamic light and laser energy with mechanical manipulation to effectively address cellulite and subcutaneous fat. These CE Marked and FDA-cleared medical devices are designed to provide long-lasting results that improve the appearance of cellulite. Eleme Medical targets plastic surgeons, aesthetic dermatologists, medical spas, and other aesthetic physicians, positioning itself within a rapidly growing segment of the aesthetics market.

Cameron Health, Inc. is a development stage medical device company focused on creating innovative implantable electronic devices. With a team of experienced professionals, the company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems, designed for patients at risk of ventricular tachyarrhythmias. The S-ICD system includes key components such as the SQ-RX pulse generator, which delivers electrical pulses to manage cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, implanted parallel to the left sternal border. Additionally, the Q-TECH programmer wirelessly communicates with the SQ-RX device, enhancing patient management. Cameron Health aims to provide advanced treatment options that were previously unattainable, leveraging state-of-the-art technologies to address complex medical challenges.

NovaSys Health is a prominent provider of managed healthcare services, operating one of the largest health plans in Arkansas. With approximately 11,000 contracted providers in the region and over 4,300 in Arkansas, the company emphasizes strong relationships with healthcare providers. It offers a range of health plans and related services, including customized solutions, provider relations, and eligibility and billing administration, catering to a diverse network of hospitals, physicians, and ancillary providers.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drugs to treat autoimmune and central nervous system disorders. The company employs a unique precision deuterium chemistry platform to modify the properties of validated drug molecules, resulting in a diverse pipeline of new chemical entities. Key product candidates include CTP-543, which is in Phase III trials for alopecia areata, and CTP-692, undergoing Phase II trials for schizophrenia. Additionally, AVP-786, a combination therapy for neurologic and psychiatric disorders, is also in Phase III trials. Concert Pharmaceuticals aims to enhance drug safety and efficacy while minimizing research and development risks and costs. Established in 2006 and based in Lexington, Massachusetts, the company has formed strategic collaborations with several pharmaceutical partners to advance its innovative drug development efforts.

Spiration, Inc., also known as Olympus Respiratory America, is a medical device company based in Redmond, Washington. Founded in 1999, the company specializes in the development of innovative solutions for the treatment of lung diseases and air leaks. Its flagship product, the IBV valve system, is a minimally invasive device designed to redirect airflow from affected areas of the lung to healthier regions, addressing both acute and chronic conditions such as emphysema and prolonged air leaks. Operating as a subsidiary of Olympus America Inc. since 2010, Spiration focuses on enhancing respiratory health through advanced medical technology.

Arbor Surgical Technologies, Inc. located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery.

North American Scientific is engaged in the design, development, manufacture, and sale of radioisotopic products for the treatment of cancer. The company offers Prospera I-125, an iodine-based seed and Prospera Pd-103, a palladium-based seed for the treatment of prostate cancer; SurTRAK needles and strands used primarily for the treatment of prostate cancer; and STP-110 Precision Stepper and RTP-6000 Precision Stabilizer equipment, which positions and holds the trans-rectal ultrasound probe during the LDR brachytherapy procedure as well as radiation shielding and needle loading accessories such as horizontal needle box; and needle-loading shield, box, and carousel. The company also offers ClearPath, a multi-catheter breast brachytherapy device for accelerated partial breast irradiation treatment for women with early-stage breast cancer. North American Scientific was founded in 1987 and is based in Chatsworth, California, United States.

Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. Its product offerings include the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for treating pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system suitable for various surgical approaches. The company serves a diverse customer base across the United States, Canada, Belgium, France, and Germany. Founded in 2004, Benvenue Medical is headquartered in Santa Clara, California, and is focused on developing innovative surgical solutions that enhance patient outcomes and restore spinal alignment.

Calistoga Pharmaceuticals, Inc. specializes in developing innovative oral medications that target specific isoforms of the PI3 kinase pathway, aiming to enhance the health outcomes of patients suffering from cancer and inflammatory diseases. This critical cellular pathway plays a significant role in cell survival and the activation of immune cells. The company's lead product, CAL-101, is an oral delta-isoform selective PI3K inhibitor that has shown promising clinical responses in patients with B-cell malignancies and is currently under evaluation in various clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals has a robust pipeline of proprietary compounds that selectively inhibit other isoforms of the PI3K pathway, which are in early preclinical development or poised for initial clinical trials targeting cancer and inflammatory conditions.

SquareOne is a content creation platform designed to support established personalities and content creators in the gaming industry. The company understands the unique needs of its partners and offers tailored assistance that emphasizes high-quality service over a broad reach. By providing professional support in areas such as revenue opportunities, brand growth, and technical guidance, SquareOne enables creators to thrive in a competitive landscape. The focus on individualized support helps creators to continue their growth and success in the gaming sector.

TriReme Medical, Inc. is a privately held medical device company located in Pleasanton, California, founded in 2005. The company specializes in the development, manufacturing, and distribution of advanced therapeutic technologies aimed at treating complex vascular diseases, particularly coronary artery disease (CAD) and peripheral vascular disease. TriReme Medical focuses on creating innovative stent and balloon therapies tailored for challenging anatomical scenarios, such as bifurcations, addressing significant clinical needs in these areas. By providing physicians with differentiated devices, the company aims to enhance patient outcomes in complex coronary and peripheral interventions.

Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety, Inc. was founded in 2000 through a collaboration of medical device incubators Thomas Fogarty Engineering and The Foundry, and is headquartered in Palo Alto, California.

Arete Therapeutics is a pharmaceutical company that develops small molecule therapeutics for diabetes and cardiovascular disease.

NeuroVista Corporation is a medical device company based in Seattle, Washington, focused on developing innovative technologies for the management and treatment of epilepsy in the United States. Founded in 2002 and originally known as BioNeuronics Corporation until its rebranding in 2007, NeuroVista aims to address the challenges faced by the approximately 3 million Americans living with epilepsy, a neurological condition characterized by unpredictable seizures. These seizures can vary significantly in severity and impact daily life, affecting individuals primarily between the ages of 15 and 64. Through its advisory technologies, NeuroVista seeks to provide tools that help mitigate the uncertainty surrounding the timing of epileptic seizures, ultimately improving the quality of life for those affected by this condition.

Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.

Reliant Technologies specializes in advanced laser treatments, particularly focusing on their proprietary Fraxel™ Laser Treatment. Founded in 2001 by a team of leading laser scientists, clinicians, and business executives, the company aims to redefine the standards of care in dermatology. Reliant's innovative technology platform addresses the challenges associated with aging and sun-damaged skin, moving beyond traditional, bulky laser systems. The company is committed to delivering effective solutions that enhance patient outcomes and streamline the treatment process, establishing a new paradigm in laser medicine.

iScience Interventional specializes in developing innovative medical technologies for ophthalmic interventions. They focus on creating advanced microcatheters and imaging systems, enabling eye specialists to precisely administer therapies to specific locations within the eye. Additionally, they offer medical devices for canaloplasty procedures.

Aspen Medtech, a Bellevue, WA-based medical device incubator.

Ascend Health Corporation is a healthcare provider specialising in behavioural health. It operates inpatient and day hospital facilities offering personalised care for children, adolescents, adults, and seniors. Ascend focuses on integrating its services with local community healthcare systems to deliver high-quality mental health and chemical dependency treatments.

SquareOne is a content creation platform designed to support established personalities and content creators in the gaming industry. The company understands the unique needs of its partners and offers tailored assistance that emphasizes high-quality service over a broad reach. By providing professional support in areas such as revenue opportunities, brand growth, and technical guidance, SquareOne enables creators to thrive in a competitive landscape. The focus on individualized support helps creators to continue their growth and success in the gaming sector.

SmoothShapes Inc., a Merrimack, N.H.-based aesthetics company.

Calistoga Pharmaceuticals, Inc. specializes in developing innovative oral medications that target specific isoforms of the PI3 kinase pathway, aiming to enhance the health outcomes of patients suffering from cancer and inflammatory diseases. This critical cellular pathway plays a significant role in cell survival and the activation of immune cells. The company's lead product, CAL-101, is an oral delta-isoform selective PI3K inhibitor that has shown promising clinical responses in patients with B-cell malignancies and is currently under evaluation in various clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals has a robust pipeline of proprietary compounds that selectively inhibit other isoforms of the PI3K pathway, which are in early preclinical development or poised for initial clinical trials targeting cancer and inflammatory conditions.

Visiogen, Inc. is an ophthalmic medical device company focused on creating innovative vision solutions for cataract patients, including those with presbyopia. The company's flagship product is the Synchrony dual optic accommodating intraocular lens (IOL), designed to deliver a seamless vision experience across near, intermediate, and distance ranges without the need for corrective eyewear. To enhance surgical efficiency, the Synchrony IOL is supplied in a pre-loaded injector, minimizing lens handling during procedures. This advanced technology has received CE Mark approval in Europe and is currently undergoing clinical trials in the United States, reflecting Visiogen's commitment to improving patient outcomes in cataract surgery.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at improving near vision. Founded in 2001, the company develops and markets innovative solutions for presbyopia, including the KAMRA inlay, which helps patients restore their near vision without compromising distance vision. Additionally, AcuFocus offers the IC-8 IOL, a small aperture lens designed for cataract patients, providing a broad range of vision from near to far distances. The company also produces the AcuTarget HD, a diagnostic and surgical planning instrument that assists in the optimal treatment selection for various eye conditions such as LASIK, cataracts, and dry eye. AcuFocus distributes its products through partners across the Americas, Asia-Pacific, Europe, and the Middle East, serving both physicians and patients in the vision care market.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

NBI Development is an implantable medical device company focused on the development of novel neuromodulation therapies. The company develops neuromodulation, the use of electrical impulses to manage activity in the nervous system.

Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drugs to treat autoimmune and central nervous system disorders. The company employs a unique precision deuterium chemistry platform to modify the properties of validated drug molecules, resulting in a diverse pipeline of new chemical entities. Key product candidates include CTP-543, which is in Phase III trials for alopecia areata, and CTP-692, undergoing Phase II trials for schizophrenia. Additionally, AVP-786, a combination therapy for neurologic and psychiatric disorders, is also in Phase III trials. Concert Pharmaceuticals aims to enhance drug safety and efficacy while minimizing research and development risks and costs. Established in 2006 and based in Lexington, Massachusetts, the company has formed strategic collaborations with several pharmaceutical partners to advance its innovative drug development efforts.

Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

LipoScience is a Raleigh, North Carolina-based company specializing in personalized diagnostics through the use of nuclear magnetic resonance (NMR) technology. The company has developed the NMR LipoProfile test, its flagship diagnostic tool, which quantitatively measures low density lipoprotein particles (LDL-P) in blood samples. This test provides physicians and patients with critical information to tailor heart disease risk management effectively. Since its inception, LipoScience has seen significant adoption, with over 8 million NMR LipoProfile tests ordered to date.

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drugs to treat autoimmune and central nervous system disorders. The company employs a unique precision deuterium chemistry platform to modify the properties of validated drug molecules, resulting in a diverse pipeline of new chemical entities. Key product candidates include CTP-543, which is in Phase III trials for alopecia areata, and CTP-692, undergoing Phase II trials for schizophrenia. Additionally, AVP-786, a combination therapy for neurologic and psychiatric disorders, is also in Phase III trials. Concert Pharmaceuticals aims to enhance drug safety and efficacy while minimizing research and development risks and costs. Established in 2006 and based in Lexington, Massachusetts, the company has formed strategic collaborations with several pharmaceutical partners to advance its innovative drug development efforts.

Cameron Health, Inc. is a development stage medical device company focused on creating innovative implantable electronic devices. With a team of experienced professionals, the company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems, designed for patients at risk of ventricular tachyarrhythmias. The S-ICD system includes key components such as the SQ-RX pulse generator, which delivers electrical pulses to manage cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, implanted parallel to the left sternal border. Additionally, the Q-TECH programmer wirelessly communicates with the SQ-RX device, enhancing patient management. Cameron Health aims to provide advanced treatment options that were previously unattainable, leveraging state-of-the-art technologies to address complex medical challenges.

Concuity is a prominent provider of revenue cycle management software and services, focused on enhancing the efficiency of healthcare organizations. The company specializes in areas such as contract profitability, contract compliance, denial management, and overall revenue process improvement. By offering a fully web-based and scalable solution, Concuity empowers healthcare entities with the visibility and control necessary to negotiate fair contracts, adhere to contractual obligations, and identify and recover underpaid or denied accounts. Its solutions are tailored to incorporate unique business rules and payer terms, allowing organizations to manage their revenue more effectively throughout its lifecycle.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Spiration, Inc., also known as Olympus Respiratory America, is a medical device company based in Redmond, Washington. Founded in 1999, the company specializes in the development of innovative solutions for the treatment of lung diseases and air leaks. Its flagship product, the IBV valve system, is a minimally invasive device designed to redirect airflow from affected areas of the lung to healthier regions, addressing both acute and chronic conditions such as emphysema and prolonged air leaks. Operating as a subsidiary of Olympus America Inc. since 2010, Spiration focuses on enhancing respiratory health through advanced medical technology.

Reliant Technologies specializes in advanced laser treatments, particularly focusing on their proprietary Fraxel™ Laser Treatment. Founded in 2001 by a team of leading laser scientists, clinicians, and business executives, the company aims to redefine the standards of care in dermatology. Reliant's innovative technology platform addresses the challenges associated with aging and sun-damaged skin, moving beyond traditional, bulky laser systems. The company is committed to delivering effective solutions that enhance patient outcomes and streamline the treatment process, establishing a new paradigm in laser medicine.

Habit OPCO is a healthcare company focused on providing treatment for opiate addiction in the United States. It offers medication-assisted treatment and counseling services aimed at helping individuals overcome addiction to opiates. The company operates 20 program sites and two mobile van units across several states, including Massachusetts, Vermont, New Jersey, New Hampshire, and Pennsylvania. Through its comprehensive approach, Habit OPCO supports patients in their recovery journey, addressing both the physical and psychological aspects of addiction.

Oculir develops non-invasive glucose meter that measures glucose from the conjunctiva of the eye.

Cameron Health, Inc. is a development stage medical device company focused on creating innovative implantable electronic devices. With a team of experienced professionals, the company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems, designed for patients at risk of ventricular tachyarrhythmias. The S-ICD system includes key components such as the SQ-RX pulse generator, which delivers electrical pulses to manage cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, implanted parallel to the left sternal border. Additionally, the Q-TECH programmer wirelessly communicates with the SQ-RX device, enhancing patient management. Cameron Health aims to provide advanced treatment options that were previously unattainable, leveraging state-of-the-art technologies to address complex medical challenges.

Radiant Medical is a private medical device company based in Redwood City, California, founded in 1999. The company specializes in endovascular temperature therapy, focusing on innovative solutions for the treatment of heart, brain, and kidney disorders. Radiant Medical's primary product is a comprehensive system that includes a single-use central venous heat exchange balloon catheter, a heat exchange cassette, a microprocessor-driven controller, and an integrated temperature sensor. This system enables healthcare providers to safely and efficiently control patient core body temperature, allowing for rapid cooling, maintenance, and warming as needed during medical procedures.

Centerre Healthcare Corporation is a provider of rehabilitation hospitals, specializing in a variety of programs aimed at aiding recovery from strokes, brain injuries, spinal cord injuries, burns, traumatic injuries, and orthopedic issues. Established in 2002 and headquartered in Brentwood, Tennessee, the company focuses on delivering comprehensive inpatient rehabilitation services that address the medical, psychological, social, and functional needs of patients and their families. Through its specialized rehabilitation programs, Centerre Healthcare supports patients in regaining their independence following injuries or illnesses.

Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.

Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

iScience Surgical, Inc. is a privately-held company founded in 1999. It is developing high resolution imaging systems and microsurgical instruments for the treatment of glaucoma. The Company's products are designed to complement existing glaucoma surgical techniques and serve as a platform for a new generation of minimally invasive procedures. Glaucoma is a sight threatening circulatory disorder of the eye that affects approximately 4.2 million Americans and 69 million people worldwide. More than $2 billion is spent annually on glaucoma medications and treatments worldwide, the majority of which are unable to restore the eye's natural drainage process.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

SpinalMotion is a private company focused on preserving spinal motion for patients suffering from degenerative disc disease. Founded in 2004, the company specializes in the development of innovative artificial disc implants that utilize proprietary Kineflex Technology, designed to maintain the natural movement of the spine while offering low wear and improved longevity. Since obtaining FDA approval in 2005 to conduct clinical trials for lumbar and cervical artificial discs in the United States, SpinalMotion has built on its international clinical experience to enhance patient outcomes. The company has attracted investment from notable partners, including Southern Medical, Three Arch Partners, Skyline Ventures, and MedVenture Associates, to further its mission of enabling patients to lead pain-free and healthy lives.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Reliant Technologies specializes in advanced laser treatments, particularly focusing on their proprietary Fraxel™ Laser Treatment. Founded in 2001 by a team of leading laser scientists, clinicians, and business executives, the company aims to redefine the standards of care in dermatology. Reliant's innovative technology platform addresses the challenges associated with aging and sun-damaged skin, moving beyond traditional, bulky laser systems. The company is committed to delivering effective solutions that enhance patient outcomes and streamline the treatment process, establishing a new paradigm in laser medicine.

VisionCare Ophthalmic Technologies, Inc., established in 1997 and headquartered in Saratoga, California, is a specialty medical device company dedicated to improving vision for individuals with untreatable retinal disorders. The company focuses on the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices. Its flagship product, the Implantable Miniature Telescope (IMT), is an FDA-approved device designed to enhance vision in patients with end-stage age-related macular degeneration (AMD). The IMT is integral to the CentraSight treatment program, which guides patients through diagnosis, surgical evaluation, and postoperative care. VisionCare's mission is to restore visual functionality and improve quality of life for individuals with untreatable retinal disorders, primarily focusing on End-Stage AMD, the leading cause of blindness in older Americans.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at improving near vision. Founded in 2001, the company develops and markets innovative solutions for presbyopia, including the KAMRA inlay, which helps patients restore their near vision without compromising distance vision. Additionally, AcuFocus offers the IC-8 IOL, a small aperture lens designed for cataract patients, providing a broad range of vision from near to far distances. The company also produces the AcuTarget HD, a diagnostic and surgical planning instrument that assists in the optimal treatment selection for various eye conditions such as LASIK, cataracts, and dry eye. AcuFocus distributes its products through partners across the Americas, Asia-Pacific, Europe, and the Middle East, serving both physicians and patients in the vision care market.

NeuroBionics Corp. researches and develops medical devices for the treatment of neurological disorders such as Parkinson’s disease, epilepsy, obesity, and depression.

Concuity is a prominent provider of revenue cycle management software and services, focused on enhancing the efficiency of healthcare organizations. The company specializes in areas such as contract profitability, contract compliance, denial management, and overall revenue process improvement. By offering a fully web-based and scalable solution, Concuity empowers healthcare entities with the visibility and control necessary to negotiate fair contracts, adhere to contractual obligations, and identify and recover underpaid or denied accounts. Its solutions are tailored to incorporate unique business rules and payer terms, allowing organizations to manage their revenue more effectively throughout its lifecycle.

Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

Vascular Architects Inc., established in 1997 by renowned surgeon Dr. Thomas J. Fogarty, specializes in designing, manufacturing, and marketing innovative devices for treating vascular stenoses, occlusions, and non-vascular obstructions. Their primary focus is on peripheral vascular disease, which involves reduced or lost blood flow due to narrowed or closed arteries. The company's product portfolio includes intraoperative vascular instruments like Doppler probes, laparoscopic Doppler systems, and oxygen analyzing monitors, used across various surgical specialties such as cardiovascular, urology, gynecology, neurology, and plastic surgery. Vascular Architects is led by an experienced team of technical, clinical, and business professionals, with key opinion leaders in interventional and vascular surgery communities serving on their Scientific Advisory Board.

Vitra Bioscience, a venture-backed biotechnology company, is developing novel technologies for comprehensive cellular analysis. The Company’s strategic objective is to create breakthrough solutions that enable users to acquire more informative data in less time, allowing for better decision-making. By applying modern imaging technology with proprietary consumables and software, Vitra Bioscience intends to develop and commercialize products that turn serial steps into parallel ones providing users with a complete tool set for their individual research needs.

LipoSonix, Inc. operates as a medical device company. The company develops non-invasive body sculpting products for aesthetic applications. The company was founded in 1999 and is based in Bothell, Washington. As of July 1, 2008, LipoSonix, Inc. operates as a subsidiary of Medicis Pharmaceutical Corp.

Evalve, Inc. engages in the design, development, manufacture, and marketing of devices that enable the repair of cardiac valves. It provides a non-surgical mitral valve repair system consisting of a steerable guide catheter, a clip delivery system, and an implant device that is used by interventional cardiologists to reduce mitral regurgitation. The company was incorporated in 1999 and is based in Menlo Park, California.

Coalescent Surgical, Inc. develops advanced technology for blood vessel anastomoses. Its surgical's U-CLIP anastomotic device enables heart surgeons to create anastomoses without tying knots or managing sutures.